Azenta, Inc. (AZTA) can sell. Click on Rating Page for detail.
The price of Azenta, Inc. (AZTA) is 40.62 and it was updated on 2025-03-12 01:26:45.
Currently Azenta, Inc. (AZTA) is in overvalued.
News |
---|
![]() Azenta, Inc. (AZTA) Q1 2025 Earnings Call Transcript
|
![]() Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024
|
![]() Azenta Announces the Election of Dipal Doshi to its Board of Directors
|
![]() Azenta Announces Fiscal 2025 First Quarter Earnings Conference Call and Webcast
|
![]() UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence
|
StockPrice Release |
---|
![]() Azenta announces ceo succession plan
|
![]() Azenta announces cfo transition
|
![]() Azenta announces the acquisition of ziath
|
News |
---|
Azenta (AZTA) Surges 7.2%: Is This an Indication of Further Gains?
|
Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600
|
Azenta to Participate in Stephens Annual Investment Conference
|
Azenta, Inc. (AZTA) Q4 2024 Earnings Call Transcript
|
Azenta (AZTA) Q4 Earnings Top Estimates
|
Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO
|
Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast
|
Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
|
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
|
GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event
|
Azenta, Inc. (AZTA) Q3 2024 Earnings Call Transcript
|
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
|
Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024
|
Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
|
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
|
Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?
|
Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast
|
FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study
|
New Strong Buy Stocks for July 16th
|
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
|
Azenta to Participate in the Jefferies Global Healthcare Conference
|
Azenta (NASDAQ:AZTA) Issues FY 2024 Earnings Guidance
|
Stock Market Crash Warning: Don't Get Caught Holding These 3 Robotics Stocks
|
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
|
Azenta, Inc. (AZTA) Q2 2024 Earnings Call Transcript
|
Azenta Announces CEO Succession Plan
|
Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024
|
Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast
|
Azenta Publishes its 2023 Environmental, Social, & Governance (ESG) Report
|
Azenta to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Azenta to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum
|
Azenta, Inc. (AZTA) Q1 2024 Earnings Call Transcript
|
Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023
|
5 medical stocks growing earnings by triple digits
|
Azenta Launches the BioArc™ Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management
|
Azenta Announces Fiscal 2024 First Quarter Earnings Conference Call and Webcast
|
Azenta to Host Investor Day on March 14, 2024
|
Azenta to Participate in the 26th Annual Needham Growth Conference
|
Azenta to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
Final Trade: DISH, GLD, EWJ and AZTA
|
Azenta to Participate in the 6th Annual Evercore ISI HealthCONx Conference
|
3 Stocks to Watch After Impressive Earnings Beats
|
Azenta, Inc. (AZTA) Q4 2023 Earnings Call Transcript
|
Azenta shares jump on Q4 results, buyback plans
|
Azenta: Life Science Play Suffers A Bad Diagnosis
|
You Can't Control Activist Investors, but You Can Control What You Do About Them
|
Activist Politan Capital engages with Azenta. Here's how the firm may boost shareholder value
|
Azenta to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
Azenta to Participate in the Baird 2023 Global Healthcare Conference
|
Robo-Lab Stocks: 3 Robotics Companies Changing the Research Game
|
Biotech Bonanza: 3 Top DNA Stocks With Revolutionary Potential
|
Azenta: A Second Assessment
|
Azenta, Inc. (AZTA) Q2 2023 Earnings Call Transcript
|
Azenta (AZTA) Reports Q2 Loss, Misses Revenue Estimates
|
Top 5 Health Care Stocks That Could Blast Off This Month - Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)
|
Azenta, Inc. (AZTA) Q1 2023 Earnings Call Transcript
|
Down -23.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Brooks (AZTA)
|
Azenta (AZTA) Beats Q1 Earnings Estimates
|
Azenta Announces Fiscal 2023 First Quarter Earnings Conference Call and Webcast
|
Azenta: Excellence In Life Sciences Offerings
|
Azenta Surges To Two-Month High On $1.5 Billion Buyback Despite Covid Decline
|
Azenta, Inc. (AZTA) Q4 2022 Earnings Call Transcript
|
Azenta Announces Fiscal 2022 Fourth Quarter and Full Year Earnings Conference Call and Webcast
|
Azenta to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
|
Azenta, Inc. (AZTA) CEO Steve Schwartz on Q3 2022 Results - Earnings Call Transcript
|
Azenta (AZTA) Q3 Earnings Beat Estimates
|
Why Azenta Stock Is Tumbling Today
|
Azenta (AZTA) Beats Q2 Earnings and Revenue Estimates
|
Azenta, Inc. (AZTA) CEO Steve Schwartz on Q2 2022 Results - Earnings Call Transcript
|
All Hail the Balance Sheet Powerhouses
|
Can Brooks (AZTA) Climb 57% to Reach the Level Wall Street Analysts Expect?
|
Azenta, Inc. (AZTA) CEO Stephen Schwartz on Q1 2022 Results - Earnings Call Transcript
|
Azenta (AZTA) Beats Q1 Earnings and Revenue Estimates
|
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
|
Brooks (AZTA) Loses 7.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
Save Your Portfolio by Getting Rid of These 4 Toxic Stocks
|
Azenta: Hyper-Focus On Life Sciences Will Unleash Growth But Wait For A Pullback
|